In recent years, many institutions have cropped up in the field of cancer research. Among the prominent firms in the sector is Clay Siegall’s Seattle Genetics, whose cutting-edge discoveries have taken the science world by storm. A testament to this unprecedented success is the upsurge of the company’s stock, which has multiplied threefold within the past five years.
Throughout his illustrious career, Clay Siegall has been devoted towards mitigating the effects of cancer. For this reason, he has spent nineteen years of his life working with Seattle Genetics to find a remedy to this menace. Under his stewardship, Seattle Genetics has transformed into an industry trailblazer in the field of cancer research, creating revolutionary treatments in the process.
After receiving his doctorate, Clay delved into the biomedical industry, landing his first job at Bristol-Myers Squibb Pharmaceutical. He later moved to the National Cancer Institute as an associate, after which he established Seattle Genetics. Clay’s prosperous career path is attributed to his relentlessness in investing in modern research as well a burning impetus to alleviate the pain of cancer patients. This commitment has resulted in the creation of innovative therapies, including ADCETRIS, which received FDA approval in 2011.
As good a researcher as he is, Clay is also a competent entrepreneur. His excellent commercial skills were demonstrated when he raised over $1.2 billion for his firm, sourcing money firm both public and individual funds. The money, used as capital, has funded a myriad of projects art Seattle Genetics. As a symbol of acknowledgment, the University of Maryland bequeathed Clay with the Alumnus of the Year award. Also, the Pacific Northwest chapter of Ernst & Young bestowed the Entrepreneur of the Year accolade on him.
All in all, Clay Siegall is at the vanguard in the fight against cancer. In addition to being credited for an array of patents, he regularly releases publications that share his knowledge on the subject.
About Clay Siegall
Clay Siegall is a renowned authority in cancer research. He has earned his respect through overseeing the development of ground-breaking cancer therapies that seek to mitigate the effects of cancer. Clay is the incumbent CEO of Seattle Genetics, a leading cancer research institution.